ClinicalTrials.gg
CompletedNCT00891735HARBORUpdated Jan 18, 2013Results posted

A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)

A Phase 3 interventional study of Ranibizumab in Age-related Macular Degeneration, sponsored by Genentech, Inc.. Completed at 99 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2013-01-18.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,097
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
3rd of 124
1,097 · median 64
Started
2009
with 7 others
Phase 3
31 of 125
2 open now
Registered
46th of 125
by date
Lead sponsor
11 of 125
Genentech, Inc.

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 3rd largest by enrollment of the 124 interventional ones that give a count, is one of 8 that started in 2009, is one of 31 in phase 3, and was the 46th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

This is a Phase III, multicenter, randomized, double-masked, dose-comparison study of the efficacy and safety of ranibizumab injection administered intravitreally to patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Results are presented for the first 12 months of the study.

03

Conditions studied

  • Age-related Macular Degeneration

Keywords

  • Lucentis
  • AMD
  • Age-related macular degeneration
  • Subfoveal neovascular age-related macular degeneration
  • Wet AMD
  • Macular degeneration
  • Ranibizumab
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For sexually active women of , agreement to the use of an appropriate form of (or abstinence) for the duration of the study.

Ocular Inclusion Criteria (Study Eye)

  • Best corrected visual acuity (BCVA), using Early Treatment Diabetic Retinopathy Study (ETDRS) charts, of 20/40-20/320 (Snellen equivalent).
  • Choroidal neovascularization (CNV) lesions with classic CNV component, occult CNV, or with some classic CNV component were permissible.
  • Total area of lesion \< 12 disc area or 30.48 mm\^2.

Exclusion criteria

Exclusion Criteria:

  • History of vitrectomy surgery, submacular surgery, or other surgical intervention for age-related macular degeneration (AMD) in the study eye.
  • Prior treatment with Visudyne(R), external-beam radiation therapy, or transpupillary thermotherapy (TTT) in the study eye.
  • Previous intravitreal drug delivery (eg, intravitreal injection, anti-angiogenic drugs, or device implantation) in the study eye.
  • Previous treatment or participation in a clinical trial involving anti-angiogenic drugs (Avastin(R), anecortave acetate, protein kinase C inhibitors, etc), in the non-study eye within 3 months of Day 0 (first day of treatment). The patient may not have received Lucentis(R) or Macugen(R) in the non-study eye within 7 days of Day 0.
  • Treatment with Visudyne(R) in the non-study eye \< 7 days preceding Day 0.
  • Subretinal hemorrhage in the study eye that involves the center of the fovea, if the size of the hemorrhage is either > 50% of the total area of the lesion or > 1 disc area (2.54 mm\^2) in size.
  • Subfoveal fibrosis or atrophy in the study eye.
  • CNV in either eye due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia.
  • Retinal pigment epithelial tear involving the macula in the study eye.
  • Any concurrent intraocular condition in the study eye (eg, cataract or diabetic retinopathy) that, in the opinion of the investigator, could either: Require medical or surgical intervention during the 24-month study period to prevent or treat visual loss that might result from that condition; or if allowed to progress untreated, could likely contribute to loss of at least 2 Snellen equivalent lines of best corrected visual acuity (BCVA) over the 24-month study period.
  • Uncontrolled blood pressure.
  • Atrial fibrillation not managed by patient's primary care physician or cardiologist within 3 months of screening visit.
  • History of stroke within the last 3 months of screening visit.
  • History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use an drug or that might affect interpretation of the results of the study or renders the patient at high risk for treatment complications.
  • Current treatment for active systemic infection.
  • Active .
  • History of allergy to fluorescein, not amenable to treatment.
  • Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,097 participants (actual)

Study arms

  • Experimental
    Ranibizumab 0.5 mg monthly

    Patients received ranibizumab 0.5 mg monthly administered intravitreally for 24 months.

    Drug: Ranibizumab

  • Experimental
    Ranibizumab 2.0 mg monthly

    Patients received ranibizumab 2.0 mg monthly administered intravitreally for 24 months.

    Drug: Ranibizumab

  • Experimental
    Ranibizumab 0.5 mg as-needed (pro re nata [PRN])

    Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 21 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.

    Drug: Ranibizumab

  • Experimental
    Ranibizumab 2.0 mg as-needed (pro re nata [PRN])

    Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 21 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally.

    Drug: Ranibizumab

Interventions

  • Sterile solution for intravitreal injection.

    Also known as: Lucentis

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12

    BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. A decrease in the BCVA score indicates a worsening of vision. A positive change score indicates improvement.

    Time frame: Baseline to Month 12

Secondary outcomes

  1. Number of Ranibizumab Injections up to But Not Including Month 12

    Time frame: Baseline to Month 12

  2. Percentage of Patients Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Month 12

    BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.

    Time frame: Baseline to Month 12

  3. Percentage of Patients With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better at Month 12

    VA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart starting at a test distance of 4 meters. An increase in the number of lines read correctly by the patient in the ETDRS chart indicates an improvement of vision. The Snellen equivalent of 20/40 is 14 lines correctly read in the EDTRS chart.

    Time frame: Month 12

  4. Percentage of Patients With no Evidence of Fluid From Choroidal Neovascularization (CNV) at Month 12

    The presence of fluid from choroidal neovascularization (CNV) was assessed by spectral domain optical coherence tomography (SD-OCT). No evidence of fluid was defined as no subretinal fluid thickness, no cystoid spaces, no intraretinal fluid, no pigment epithelial defect thickness, and average central subfield thickness \< 270 µm.

    Time frame: Month 12

  5. Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12

    Central foveal thickness was assessed by spectral domain optical coherence tomography (SD-OCT).

    Time frame: Baseline to Day 7 and Months 1, 2, 3, 4, 6, 9, and 12

  6. Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12

    Macular volume was assessed by spectral domain optical coherence tomography (SD-OCT).

    Time frame: Baseline to Day 7 and Months 1, 2, 3, 4, 6, 9, and 12

  7. Change From Baseline in the Total Area of Choroidal Neovascularization (CNV) and Choroidal Neovascular Leakage at Month 12

    The total area of choroidal neovascularization (CNV) and choroidal neovascular leakage was assessed with fluorescein angiography (FA). Area was measured in disc area units; 1 disc area unit = 2.54 mm\^2.

    Time frame: Baseline to Month 12

07

Results

Posted Jan 18, 2013

Participant flow

Participant flow — Overall Study
MilestoneRanibizumab 0.5 mg MonthlyRanibizumab 2.0 mg MonthlyRanibizumab 0.5 mg As-needed (Pro re Nata [PRN])Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])
Started275274275273
Completed258258263258
Not completed17161215
Withdrew: Adverse event2020
Withdrew: Death8545
Withdrew: Lost to follow-up2222
Withdrew: Physician's decision to withdraw patient1000
Withdrew: Patient's decision to withdraw4948

Outcome measures

PrimaryChange From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12

BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. A decrease in the BCVA score indicates a worsening of vision. A positive change score indicates improvement.

Time frame:
Baseline to Month 12
Reported as:
Mean · Letters
Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12
LettersRanibizumab 0.5 mg MonthlyRanibizumab 2.0 mg MonthlyRanibizumab 0.5 mg As-needed (Pro re Nata [PRN])Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])
Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 1210.1 ± 13.39.2 ± 14.68.2 ± 13.38.6 ± 13.8
SecondaryNumber of Ranibizumab Injections up to But Not Including Month 12
Time frame:
Baseline to Month 12
Reported as:
Mean · Injections
Number of Ranibizumab Injections up to But Not Including Month 12
InjectionsRanibizumab 0.5 mg MonthlyRanibizumab 2.0 mg MonthlyRanibizumab 0.5 mg As-needed (Pro re Nata [PRN])Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])
Number of Ranibizumab Injections up to But Not Including Month 1211.3 ± 1.811.2 ± 2.17.7 ± 2.76.9 ± 2.4
SecondaryPercentage of Patients Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Month 12

BCVA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.

Time frame:
Baseline to Month 12
Reported as:
Number · Percentage of patients
Percentage of Patients Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Month 12
Percentage of patientsRanibizumab 0.5 mg MonthlyRanibizumab 2.0 mg MonthlyRanibizumab 0.5 mg As-needed (Pro re Nata [PRN])Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])
Percentage of Patients Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) From Baseline at Month 1234.5 (28.9 to 40.2)36.1 (30.4 to 41.8)30.2 (24.8 to 35.6)33.0 (27.4 to 38.5)
SecondaryPercentage of Patients With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better at Month 12

VA was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart starting at a test distance of 4 meters. An increase in the number of lines read correctly by the patient in the ETDRS chart indicates an improvement of vision. The Snellen equivalent of 20/40 is 14 lines correctly read in the EDTRS chart.

Time frame:
Month 12
Reported as:
Number · Percentage of patients
Percentage of Patients With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better at Month 12
Percentage of patientsRanibizumab 0.5 mg MonthlyRanibizumab 2.0 mg MonthlyRanibizumab 0.5 mg As-needed (Pro re Nata [PRN])Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])
Percentage of Patients With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better at Month 1252.4 (46.5 to 58.3)50.0 (44.1 to 55.9)46.2 (40.3 to 52.1)43.6 (37.7 to 49.5)
SecondaryPercentage of Patients With no Evidence of Fluid From Choroidal Neovascularization (CNV) at Month 12

The presence of fluid from choroidal neovascularization (CNV) was assessed by spectral domain optical coherence tomography (SD-OCT). No evidence of fluid was defined as no subretinal fluid thickness, no cystoid spaces, no intraretinal fluid, no pigment epithelial defect thickness, and average central subfield thickness \< 270 µm.

Time frame:
Month 12
Reported as:
Number · Percentage of patients
Percentage of Patients With no Evidence of Fluid From Choroidal Neovascularization (CNV) at Month 12
Percentage of patientsRanibizumab 0.5 mg MonthlyRanibizumab 2.0 mg MonthlyRanibizumab 0.5 mg As-needed (Pro re Nata [PRN])Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])
Percentage of Patients With no Evidence of Fluid From Choroidal Neovascularization (CNV) at Month 125.1 (2.5 to 7.7)5.8 (3.1 to 8.6)2.9 (0.9 to 4.9)4.8 (2.2 to 7.3)
SecondaryChange From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12

Central foveal thickness was assessed by spectral domain optical coherence tomography (SD-OCT).

Time frame:
Baseline to Day 7 and Months 1, 2, 3, 4, 6, 9, and 12
Reported as:
Mean · µm
Change From Baseline in Central Foveal Thickness at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12
µmRanibizumab 0.5 mg MonthlyRanibizumab 2.0 mg MonthlyRanibizumab 0.5 mg As-needed (Pro re Nata [PRN])Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])
Day 7-104.9 ± 130.3-84.9 ± 111.3-103.5 ± 141.3-100.6 ± 123.4
Month 1-141.5 ± 137.5-128.6 ± 133.3-132.6 ± 148.2-146.0 ± 144.3
Month 2-152.5 ± 142.4-140.3 ± 131.1-142.9 ± 141.6-156.9 ± 145.0
Month 3-157.0 ± 143.8-147.9 ± 134.3-154.5 ± 147.9-164.9 ± 144.5
Month 4-164.0 ± 146.6-151.8 ± 143.3-142.7 ± 153.6-159.7 ± 148.8
Month 6-162.0 ± 150.0-149.2 ± 144.0-147.5 ± 151.9-159.1 ± 149.6
Month 9-164.5 ± 151.8-153.1 ± 144.8-153.5 ± 147.1-157.8 ± 155.6
Month 12-172.0 ± 150.5-163.3 ± 142.6-161.2 ± 152.3-172.4 ± 148.6
SecondaryChange From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12

Macular volume was assessed by spectral domain optical coherence tomography (SD-OCT).

Time frame:
Baseline to Day 7 and Months 1, 2, 3, 4, 6, 9, and 12
Reported as:
Mean · mm^3
Change From Baseline in Macular Volume at Day 7 and Months 1, 2, 3, 4, 6, 9, and 12
mm^3Ranibizumab 0.5 mg MonthlyRanibizumab 2.0 mg MonthlyRanibizumab 0.5 mg As-needed (Pro re Nata [PRN])Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])
Day 7-0.79 ± 0.80-0.80 ± 0.76-0.72 ± 0.87-0.81 ± 0.76
Month 1-1.26 ± 1.06-1.30 ± 1.15-1.16 ± 1.03-1.38 ± 1.18
Month 2-1.34 ± 1.17-1.49 ± 1.31-1.30 ± 1.13-1.47 ± 1.25
Month 3-1.42 ± 1.25-1.51 ± 1.32-1.43 ± 1.33-1.55 ± 1.28
Month 4-1.42 ± 1.22-1.56 ± 1.31-1.31 ± 1.24-1.48 ± 1.27
Month 6-1.47 ± 1.25-1.61 ± 1.34-1.35 ± 1.33-1.48 ± 1.36
Month 9-1.55 ± 1.41-1.67 ± 1.34-1.35 ± 1.31-1.48 ± 1.33
Month 12-1.54 ± 1.31-1.66 ± 1.37-1.41 ± 1.36-1.49 ± 1.35
SecondaryChange From Baseline in the Total Area of Choroidal Neovascularization (CNV) and Choroidal Neovascular Leakage at Month 12

The total area of choroidal neovascularization (CNV) and choroidal neovascular leakage was assessed with fluorescein angiography (FA). Area was measured in disc area units; 1 disc area unit = 2.54 mm\^2.

Time frame:
Baseline to Month 12
Reported as:
Mean · Disc area units
Change From Baseline in the Total Area of Choroidal Neovascularization (CNV) and Choroidal Neovascular Leakage at Month 12
Disc area unitsRanibizumab 0.5 mg MonthlyRanibizumab 2.0 mg MonthlyRanibizumab 0.5 mg As-needed (Pro re Nata [PRN])Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])
Change in the total area of CNV-2.14 ± 2.40-2.42 ± 2.38-1.74 ± 2.22-1.98 ± 2.39
Change in the total area of CNV leakage-2.35 ± 2.39-2.63 ± 2.34-2.01 ± 2.28-2.22 ± 2.48

Adverse events

Collected over Adverse events were recorded from Baseline (first treatment day) through Month 12.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab 0.5 mg Monthly—66/274 (24.1%)240/274 (87.6%)
Ranibizumab 2.0 mg Monthly—54/274 (19.7%)243/274 (88.7%)
Ranibizumab 0.5 mg As-needed (Pro re Nata [PRN])—57/275 (20.7%)250/275 (90.9%)
Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])—54/272 (19.9%)239/272 (87.9%)
Most frequent serious events
Showing 10 of 194
Most frequent serious events
EventRanibizumab 0.5 mg MonthlyRanibizumab 2.0 mg MonthlyRanibizumab 0.5 mg As-needed (Pro re Nata [PRN])Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])
Cardiac failure congestiveCardiac disorders6/2741/2742/2752/272
PneumoniaInfections and infestations5/2745/2746/2753/272
Myocardial infarctionCardiac disorders5/2741/2740/2753/272
Atrial fibrillationCardiac disorders2/2741/2744/2754/272
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/2740/2741/2754/272
FallInjury, poisoning and procedural complications1/2742/2741/2753/272
Hip fractureInjury, poisoning and procedural complications1/2741/2743/2753/272
Cardiac arrestCardiac disorders3/2740/2740/2751/272
Visual acuity reducedEye disorders0/2743/2742/2750/272
DehydrationMetabolism and nutrition disorders3/2741/2741/2750/272
Most frequent other events
Showing 10 of 17
Most frequent other events
EventRanibizumab 0.5 mg MonthlyRanibizumab 2.0 mg MonthlyRanibizumab 0.5 mg As-needed (Pro re Nata [PRN])Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])
Conjunctival haemorrhageEye disorders63/27451/27448/27541/272
Vitreous detachmentEye disorders22/27421/27416/27527/272
SinusitisInfections and infestations12/2747/27427/2758/272
Vitreous floatersEye disorders26/27415/27411/27517/272
Eye painEye disorders15/27425/27416/27523/272
Vitreous detachmentEye disorders20/27424/27417/27513/272
NasopharyngitisInfections and infestations17/27410/27417/27523/272
FallInjury, poisoning and procedural complications14/27412/2748/27521/272
HypertensionVascular disorders14/27420/27421/27515/272
Macular degenerationEye disorders12/2748/27418/27515/272

Baseline characteristics

Age Continuous
Age Continuous(years)Ranibizumab 0.5 mg MonthlyRanibizumab 2.0 mg MonthlyRanibizumab 0.5 mg As-needed (Pro re Nata [PRN])Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])Total
Mean78.8 ± 8.479.3 ± 8.378.5 ± 8.378.3 ± 8.378.7 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab 0.5 mg MonthlyRanibizumab 2.0 mg MonthlyRanibizumab 0.5 mg As-needed (Pro re Nata [PRN])Ranibizumab 2.0 mg As-needed (Pro re Nata [PRN])Total
Female162170163156651
Male113104112117446
08

Study locations

99 sites
  • Phoenix, Arizona 85020, United States
  • Tucson, Arizona 85704, United States
  • Arcadia, California 91007, United States
  • Beverly Hills, California 90211, United States
  • Campbell, California 95008, United States
  • Chico, California 95973, United States
  • La Jolla, California 92093-0946, United States
  • Los Angeles, California 90033, United States
  • Los Angeles, California 90095-7000, United States
  • Mountain View, California 94040, United States
  • Oakland, California 94609, United States
  • Palm Desert, California 92211, United States
  • Poway, California 92064, United States
  • Sacramento, California 95817, United States
  • San Francisco, California 94107, United States
  • San Francisco, California 94115, United States
  • Santa Ana, California 92705, United States
  • Santa Barbara, California 93103, United States
  • Torrance, California 90503, United States
  • Ventura, California 93003, United States
  • Westlake Village, California 91361, United States
  • Aurora, Colorado 80045, United States
  • Colorado Springs, Colorado 80909, United States
  • Golden, Colorado 80401, United States
  • Danbury, Connecticut 06810, United States
  • Hamden, Connecticut 06518, United States
  • New Haven, Connecticut 06510, United States
  • New London, Connecticut 06320, United States
  • Altamonte Springs, Florida 32701, United States
  • Boynton Beach, Florida 33426, United States
  • Fort Lauderdale, Florida 33334, United States
  • Fort Myers, Florida 33912, United States
  • Palm Beach Gardens, Florida 33410, United States
  • Pensacola, Florida 32503, United States
  • Stuart, Florida 34994, United States
  • Tampa, Florida 33609, United States
  • Tampa, Florida 33612, United States
  • Winter Haven, Florida 33880, United States
  • Augusta, Georgia 30909, United States
  • Aiea, Hawaii 96701, United States
  • Chicago, Illinois 60637, United States
  • Oak Park, Illinois 60304, United States
  • Indianapolis, Indiana 46290, United States
  • Shawnee Mission, Kansas 66204, United States
  • Wichita, Kansas 67214, United States
  • Lexington, Kentucky 40509, United States
  • Paducah, Kentucky 42001, United States
  • Portland, Maine 04102, United States
  • Baltimore, Maryland 21287, United States
  • Hagerstown, Maryland 21740, United States
  • Boston, Massachusetts 02111, United States
  • Boston, Massachusetts 02114, United States
  • Worcester, Massachusetts 01605, United States
  • Jackson, Michigan 49201, United States
  • Edina, Minnesota 55435, United States
  • Saint Louis, Missouri 63144, United States
  • Lincoln, Nebraska 68506, United States
  • Las Vegas, Nevada 89144, United States
  • Lawrenceville, New Jersey 08648, United States
  • New Brunswick, New Jersey 08901, United States
  • Northfield, New Jersey 08225, United States
  • Teaneck, New Jersey 07666, United States
  • Vauxhall, New Jersey 07088, United States
  • Great Neck, New York 11021, United States
  • Lynbrook, New York 11563, United States
  • New York, New York 10021, United States
  • Rochester, New York 14620, United States
  • Shirley, New York 11967, United States
  • Asheville, North Carolina 28803, United States
  • Charlotte, North Carolina 28210, United States
  • Beachwood, Ohio 44122, United States
  • Cincinnati, Ohio 45242, United States
  • Columbus, Ohio 43212, United States
  • Portland, Oregon 97210, United States
  • Camp Hill, Pennsylvania 17011, United States
  • Huntingdon Valley, Pennsylvania 19006, United States
  • Johnstown, Pennsylvania 15904, United States
  • Philadelphia, Pennsylvania 19107, United States
  • Pittsburgh, Pennsylvania 15212, United States
  • Pittsburgh, Pennsylvania 15213, United States
  • West Mifflin, Pennsylvania 15122, United States
  • Greenville, South Carolina 29605, United States
  • Ladson, South Carolina 29456, United States
  • West Columbia, South Carolina 29169, United States
  • Rapid City, South Dakota 57701, United States
  • Nashville, Tennessee 37203, United States
  • Abilene, Texas 79606, United States
  • Austin, Texas 78705, United States
  • Desoto, Texas 75115, United States
  • Houston, Texas 77030, United States
  • McAllen, Texas 78503, United States
  • San Antonio, Texas 78240, United States
  • Temple, Texas 76508, United States
  • The Woodlands, Texas 77384, United States
  • Salt Lake City, Utah 84107, United States
  • Richmond, Virginia 23235, United States
  • Virginia Beach, Virginia 23454, United States
  • Milwaukee, Wisconsin 53226, United States
  • Casper, Wyoming 82601, United States
09

References and documents

Publications

  • Staurenghi G, Cozzi M, Sadda S, Hill L, Gune S. Characteristics that Correlate with Macular Atrophy in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration. Ophthalmol Retina. 2023 Apr;7(4):300-306. doi: 10.1016/j.oret.2022.11.002. Epub 2022 Nov 11. PubMed 36372347 ↗
  • Lally DR, Hill L, Amador-Patarroyo MJ. Subretinal Fluid Resolution and Visual Acuity in Patients with Neovascular Age-Related Macular Degeneration: A HARBOR Post Hoc Analysis. Ophthalmol Retina. 2022 Nov;6(11):1054-1060. doi: 10.1016/j.oret.2022.05.026. Epub 2022 May 30. PubMed 35654363 ↗
  • Sheth V, D'Rozario M, Gune S, Blotner S. Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis. BMJ Open Ophthalmol. 2022 Mar 9;7(1):e000957. doi: 10.1136/bmjophth-2021-000957. eCollection 2022. PubMed 35342822 ↗
  • Freund KB, Staurenghi G, Jung JJ, Zweifel SA, Cozzi M, Hill L, Blotner S, Tsuboi M, Gune S. Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR. Graefes Arch Clin Exp Ophthalmol. 2022 Aug;260(8):2437-2447. doi: 10.1007/s00417-022-05586-w. Epub 2022 Mar 3. PubMed 35239009 ↗
  • Pawloff M, Bogunovic H, Gruber A, Michl M, Riedl S, Schmidt-Erfurth U. SYSTEMATIC CORRELATION OF CENTRAL SUBFIELD THICKNESS WITH RETINAL FLUID VOLUMES QUANTIFIED BY DEEP LEARNING IN THE MAJOR EXUDATIVE MACULAR DISEASES. Retina. 2022 May 1;42(5):831-841. doi: 10.1097/IAE.0000000000003385. PubMed 34934034 ↗
  • Holekamp NM, Sadda S, Sarraf D, Guymer R, Hill L, Blotner S, Spicer G, Gune S. Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration. Am J Ophthalmol. 2022 Jan;233:8-17. doi: 10.1016/j.ajo.2021.06.029. Epub 2021 Jul 18. PubMed 34289338 ↗
  • Javaheri M, Hill L, Ghanekar A, Stoilov I. Changes in Treatment-Naive Pigment Epithelial Detachments Associated With the Initial Anti-Vascular Endothelial Growth Factor Injection: A Post Hoc Analysis From the HARBOR Trial. JAMA Ophthalmol. 2021 Feb 1;139(2):219-223. doi: 10.1001/jamaophthalmol.2020.5130. Erratum In: JAMA Ophthalmol. 2021 Feb 1;139(2):256. doi: 10.1001/jamaophthalmol.2020.6407. PubMed 33331859 ↗
  • Sadda SR, Abdelfattah NS, Lei J, Shi Y, Marion KM, Morgenthien E, Gune S, Balasubramanian S. Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020 Oct;127(10):1360-1370. doi: 10.1016/j.ophtha.2020.03.031. Epub 2020 Apr 2. PubMed 32402555 ↗
  • Khurana RN, Chang L, Day BM, Ghanekar A, Stoilov I. Timing of Peak Vision Gains in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab. Ophthalmol Retina. 2020 Aug;4(8):760-766. doi: 10.1016/j.oret.2020.02.011. Epub 2020 Feb 27. PubMed 32387055 ↗
  • Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2020 May 5;5(5):CD012208. doi: 10.1002/14651858.CD012208.pub2. PubMed 32374423 ↗
  • Khurana RN, Hill L, Ghanekar A, Gune S. Agreement of Spectral-Domain OCT with Fluorescein Leakage in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study. Ophthalmol Retina. 2020 Nov;4(11):1054-1058. doi: 10.1016/j.oret.2020.04.016. Epub 2020 Apr 28. PubMed 32353536 ↗
  • Patel Y, Miller DM, Fung AE, Hill LF, Rosenfeld PJ. Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? Ophthalmol Retina. 2020 Feb;4(2):141-147. doi: 10.1016/j.oret.2019.09.006. Epub 2019 Sep 18. PubMed 31735634 ↗
  • Khurana RN, Chang LK, Hill LF, Ghanekar A, Stoilov I. The Value of Prior Response to Anti-Vascular Endothelial Growth Factor for Age-Related Macular Degeneration: A HARBOR Subanalysis. Ophthalmol Retina. 2020 Jan;4(1):13-18. doi: 10.1016/j.oret.2019.06.008. Epub 2019 Jul 5. PubMed 31416763 ↗
  • Nassisi M, Lei J, Abdelfattah NS, Karamat A, Balasubramanian S, Fan W, Uji A, Marion KM, Baker K, Huang X, Morgenthien E, Sadda SR. OCT Risk Factors for Development of Late Age-Related Macular Degeneration in the Fellow Eyes of Patients Enrolled in the HARBOR Study. Ophthalmology. 2019 Dec;126(12):1667-1674. doi: 10.1016/j.ophtha.2019.05.016. Epub 2019 May 29. PubMed 31281056 ↗
  • Hallak JA, de Sisternes L, Osborne A, Yaspan B, Rubin DL, Leng T. Imaging, Genetic, and Demographic Factors Associated With Conversion to Neovascular Age-Related Macular Degeneration: Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2019 Jul 1;137(7):738-744. doi: 10.1001/jamaophthalmol.2019.0868. PubMed 31021381 ↗
  • Sarraf D, London NJ, Khurana RN, Dugel PU, Gune S, Hill L, Tuomi L. Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study. Ophthalmology. 2016 Oct;123(10):2213-24. doi: 10.1016/j.ophtha.2016.07.007. Epub 2016 Aug 23. PubMed 27566855 ↗
  • Frenkel RE, Shapiro H, Stoilov I. Predicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision. Br J Ophthalmol. 2016 Aug;100(8):1052-7. doi: 10.1136/bjophthalmol-2015-307575. Epub 2015 Nov 5. PubMed 26541435 ↗
  • Busbee BG, Ho AC, Brown DM, Heier JS, Suner IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013 May;120(5):1046-56. doi: 10.1016/j.ophtha.2012.10.014. Epub 2013 Jan 23. PubMed 23352196 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Aug 2011 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2009
First posted
May 1, 2009
Start
Jul 2009
Primary completionActual
Aug 2011
CompletionActual
Aug 2012
Results first posted
Jan 18, 2013
Last update
Jan 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00891735
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
May 1, 2009
Start date
Jul 2009
Primary completion
Aug 2011
Completion
Aug 2012
Results posted
Jan 18, 2013
Last update
Jan 18, 2013

Study contacts

Clinical Trials
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion